Maharashtra FDA cancels Cipla Pune unit’s drug sale licence over violations

The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licence of Cipla’s Pune unit. The action follows an inspection carried out in June. During the inspection, FDA officials found unauthorised promotional text on the packaging of Reactin Plus, a Schedule H prescription medicine. The words “analgesic and antipyretic” were printed on the packaging despite not being permitted. The source does not provide further details such as the exact date of the licence cancellation, the scope of the action, or any response from Cipla.